Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced active chronic hepatitis

G B Goldstein, K C Lam, S P Mistilis

    The American Journal of Digestive Diseases
    |March 1, 1973
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Risk of bias among Chinese-language randomized controlled trials on Chinese herbal medicine included in meta-analyses published in 2021-2022: A cross-sectional study.

    Integrative medicine research·2026
    Same author

    Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.

    Lung cancer (Amsterdam, Netherlands)·2025
    Same author

    Methodological quality of systematic reviews on orally administered Chinese herbal medicine published in Chinese between 2021 and 2022: A cross-sectional study.

    Journal of integrative medicine·2025
    Same author

    CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression.

    Clinical lung cancer·2025
    Same author

    In-Scanner Thoughts shape Resting-state Functional Connectivity: how participants "rest" matters.

    bioRxiv : the preprint server for biology·2024
    Same author

    Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.

    JTO clinical and research reports·2024